Findings

What do systematic reviews say?

777 questions · 792 findings · 40 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 232 · 29.3%GRADE not reported 3 · 0.4%Very low 218 · 27.5%Low 253 · 31.9%Moderate 76 · 9.6%High 10 · 1.3%

Eculizumab vs placebo or alternative treatment

Remission · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Change in eGFR · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
88 participants
Very low

Eculizumab vs placebo or alternative treatment

Health‐related quality of life · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Adverse events · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Eculizumab vs placebo or alternative treatment

Meningococcal infection · children and adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
100 participants
Very low

Ravulizumab vs placebo or alternative treatment

Death · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
58 participants
Very low

Ravulizumab vs placebo or alternative treatment

Requirement for KRT · adults with aHUS

1 finding from 1 review

Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
56 participants
Very low

Antibiotics vs no treatment

Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether antibiotics changes incidence of HUS compared with no treatment (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 0.57 [0.11, 2.81]
1 study · 47 participants
Very low

Bovine colostrum vs placebo

Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Incidence of HUS · patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether synsorb Pk changes incidence of HUS compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 0.93 [0.39, 2.22]
1 study · 353 participants
Very low

Synsorb Pk vs placebo

Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Need for acute dialysis · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Neurological complications · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Synsorb Pk vs placebo

Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Urtoxazumab (3.0 mg/kg) vs placebo

Incidence of HUS · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether urtoxazumab (3.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.14]
1 study · 71 participants
Very low

Urtoxazumab (3.0 mg/kg) vs placebo

Adverse events ‐ treatment emergent · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

Urtoxazumab (3.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 1 [0.84, 1.18]
1 study · 71 participants
Low

Urtoxazumab (3.0 mg/kg) vs placebo

Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 71 participants
Low

Urtoxazumab (3.0 mg/kg) vs placebo

Need for acute dialysis · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antibiotics vs no treatment

Adverse events · patients with diarrhoea due to Shiga toxin‐producing E. coli

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Urtoxazumab (3.0 mg/kg) vs placebo

Neurological complications · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli

It is very uncertain whether urtoxazumab (3.0 mg/kg) changes neurological complications compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
RR 2.06 [0.2, 21.68]
1 study · 71 participants
Very low